Physician profile
Ginger F Epling
NPI 1275151573
$2,478.36
in general payments reported to CMS, 2019-2025
31 companies · $15.33 in 2025
The $15.33 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $104 · 2022: $570 · 2023: $1,366 · 2024: $422 · 2025: $15.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,803.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $479.37 | 2021-2025 | |
| Novo Nordisk INC | $413.91 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $243.99 | 2022-2024 | Rexulti, Jynarque, Nuedexta |
| Lundbeck LLC | $106.24 | 2021-2023 | Vyepti, Rexulti |
| Astrazeneca Pharmaceuticals Lp | $102.31 | 2022-2024 | Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $98.22 | 2022-2023 | Belsomra, Vaxelis, Rotateq |
| Lilly USA, LLC | $96.75 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Mylan Specialty L.P. | $96.51 | 2022-2024 | Yupelri |
| Pfizer INC. | $92.82 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.63 | 2022-2024 | Jardiance |
| Amgen INC. | $65.52 | 2022-2024 | Evenity, Prolia, Otezla |
| Currax Pharmaceuticals LLC | $64.18 | 2022-2023 | Contrave, Onzetra Xsail |
| Astellas Pharma US INC | $58.85 | 2021-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $57.12 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $56.99 | 2022-2023 | Spravato |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $48.37 | 2022-2023 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $48.16 | 2022-2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.99 | 2023-2024 | Xifaxan, Trulance |
| Nestle Healthcare Nutrition INC. | $29.76 | 2023 | |
| Seqirus USA INC | $29.06 | 2022-2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Corium, LLC | $29.06 | 2022-2023 | Adlarity |
| Takeda Pharmaceuticals U.S.A., INC. | $21.86 | 2024 | Trintellix |
| Glaxosmithkline, LLC. | $19.59 | 2023 | Arexvy, Shingrix |
| Exact Sciences Corporation | $19.15 | 2023 | Cologuard Collection Kit |
| Impel Pharmaceuticals INC. | $14.59 | 2023 | Trudhesa |
| Esperion Therapeutics, INC. | $14.50 | 2022 | |
| Sanofi Pasteur INC. | $14.08 | 2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.27 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.25 | 2022 | |
| Ironwood Pharmaceuticals, INC | $12.95 | 2022 | |
| Medtronic, INC. | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginger Epling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.